ArticleBreast cancer research : BCR2023

SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.

Feng Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.